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Sphingolipids are ubiquitous and critical components of biological membranes. Their biosynthesis starts with
soluble precursors in the endoplasmic reticulum and culminates in the Golgi complex and plasma membrane.
Ceramides are important intermediates in the biosynthesis of sphingolipids, such as sphingomyelin, and their
overload in the membranes is injurious to cells. The major product of ceramide metabolism is sphingomyelin. We
observed that sphingomyelin synthase (SMS) 1 or SMS2 deficiencies significantly decreased plasma and liver
sphingomyelin levels. However, SMS2 but not SMS1 deficiency increased plasma ceramides. Surprisingly, SMS1
deficiency significantly increased glucosylceramide and ganglioside GM3, but SMS2 deficiency did not. To explain
these unexpected findings about modest to no significant changes in ceramides and increases in other
sphingolipids after the ablation of SMS1, we hypothesize that cells have evolved several organelle specific
mechanisms to maintain ceramide homeostasis. First, ceramides in the endoplasmic reticulum membranes are
controlled by its export to Golgi by protein mediated transfer. Second, in the Golgi, ceramide levels are modulated
by their enzymatic conversion to different sphingolipids such as sphingomyelin, and glucosylceramides.
Additionally, these sphingolipids can become part of triglyceride-rich apolipoprotein B-containing lipoproteins and
be secreted. Third, in the plasma membrane ceramide levels are maintained by ceramide/sphingomyelin cycle,
delivery to lysosomes, and efflux to extracellular plasma acceptors. All these pathways might have evolved to
ensure steady cellular ceramide levels.
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Sphingolipids include hundreds of distinct molecular
species that consist of a common eighteen carbon
amino-alcohol backbone, sphingosine. Significant infor-
mation is available about their synthesis and metabolism
[1-4]. Sphingolipids, especially ceramides and sphingo-
myelins, play important roles in maintaining membrane
function and integrity. They are found concentrated in
lipid rafts, small microdomains in various membranes
primarily in plasma membrane that are also enriched in
free cholesterol and contain specific proteins [5]. These
microdomains are well suited for specialized functions
such as cell signaling, lipid and protein sorting, choles-
terol efflux and inflammatory response in macrophages
and other cell types [5-7].* Correspondence: mhussain@downstate.edu
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reproduction in any medium, provided the orCeramides are critical mediators of cellular apoptosis
and stress responses [8]. Several mechanisms have been
attributed to ceramide-induced apoptosis. Excess
amounts of ceramides in the plasma membrane form
distinct, cholesterol-poor and ceramide-enriched mem-
brane domains that alter cellular signal transduction by
clustering of receptor molecules. These ceramide-rich
membrane platforms have been shown to be central in
the regulation of apoptosis induced by death receptor
activation, stress stimuli and growth factor deprivation
as well as in contributing to infection of some pathogens
[8]. Further, the contribution of excess ceramides to
apoptosis has been reported in several human disorders.
Cystic fibrosis transmembrane conductance regulator
(CFTR) deficiency results in increases in lung ceramide
levels due to alterations in lysosomal pH and is asso-
ciated with augmentations in cell death, inflammation
and infection susceptibility [9]. In Wilson disease, high
Cu2+ concentrations activate acid sphingomyelinase andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hepatocyte and erythrocytes [10]. High plasma ceramide
levels have been correlated with insulin resistance in
type 2 diabetic obese subjects [11] and with increased
mortality in sepsis patients [12]. In addition, ceramides
mediate inflammatory responses initiated by cytokines
or oxidized low density lipoproteins (LDL) [13,14].
Plasma ceramides may contribute to maladaptive inflam-
mation in patients with coronary heart disease [15] and
possibly correlate with an increase in LDL oxidation, be-
coming a risk factor for atherosclerosis [16]. Therefore,
ceramides appear to be proatherogenic factors and in-
jurious to arterial walls. Further, there is significant evi-
dence that inhibiting production of ceramides could
delay or prevent diseases [17]. In fact, it has been sug-
gested that ceramides are one of the most toxic lipids
that can accumulate in the obese [17]. Therefore, their
steady state cellular and plasma levels need to be tightly
regulated. Here, we briefly summarize what is known
about the synthesis and intracellular transport of cera-
mides and sphingomyelin, present recent observations
about changes in tissue and plasma sphingolipid levels
in mice deficient in sphingomyelin synthesizing
enzymes, and advance a hypothesis that cells have
evolved organelle specific mechanisms to control cera-
mide levels.
Synthesis and conversion of ceramides into
different sphingolipids
Synthesis of ceramides in the ER and their export
Sphingolipid biosynthesis starts in the endoplasmic
reticulum (ER) using non-sphingolipid hydrophilic precur-
sor molecules serine and palmitoyl-CoA [1-3] (Figure 1).
Condensation of L-serine and palmitoyl-CoA into 3-
ketodihydrosphingosine is facilitated by ER membrane
associated serine palmitoyltransferases. Next step in
sphingolipid biosynthesis is the reduction of 3-ketodi
hydrosphingosine to dihydrosphingosine by a reductase.
N-acylation of dihydrosphingosine gives rise to dihydro-
ceramide, a product that is still relatively hydrophilic.
Conversion of dihydroceramide to ceramides is facili-
tated by ceramide synthases and involves a desaturation
step. Ceramides are hydrophobic and therefore become
membrane associated. Apart from this de novo synthesis
(Figure 1, A), ceramides can also be generated via break
down of sphingomyelin in the cell membranes (Figure 1, B)
[18] and salvaged from lysosomes (Figure 1, C) after deg-
radation of sphingolipids [17].
Sphingomyelin synthase related protein (SMSr) has no
sphingomyelin synthase activity but converts [19,20]
some of the ceramide into ceramide phosphatidylethera-
mine (CPE) whose function is still unknown. Further,
ceramides can be converted to galactosylceramides in the
brain for myelin synthesis [1,2]. However, the majority ofceramides are transported from the ER to the Golgi by
ceramide transport protein (CERT) [21-23].
Conversion of ceramides to different sphingolipids in
the Golgi
In the Golgi, ceramides are converted to sphingomyelin,
glucosylceramide and then to more complex sphin-
golipids such as GM3, or to ceramide-1-phosphate
(Figure 1). These products are then transported to plasma
membrane, which is the major cellular reservoir for these
lipids. The major product of ceramide conversion is
sphingomyelin carried out by two sphingomyelin synthase
enzymes SMS1 and SMS2 [19,24]. SMS1 is found in the
Golgi, while SMS2 is predominantly found in the plasma
membranes [19,24]. SMS1 and SMS2 activities are co-
expressed in a variety of tissues and cells with different
ratios. SMS1 is the major SMS in macrophages [25], while
SMS2 is the major enzyme in the liver [26]. Others and
we have shown that SMS1 and SMS2 expression positively
correlates with sphingomyelin levels in cells and lipid rafts
[27-29]. Very little is known about the transport of differ-
ent sphingolipids out of the Golgi. It is assumed that they
are trafficked to plasma membrane via the vesicular
transport pathway that carries secretory and plasma
membrane proteins.
Ceramide/sphingomyelin cycle in the plasma membrane
Plasma membrane is enriched in SMS2 that synthesizes
sphingomyelin from ceramides as well as in sphingo-
myelinase (SMase) that hydrolyzes sphingomyelin to cer-
amides. Thus, plasma membrane ceramide levels are
balanced by the activities of these two enzymes. Further,
plasma membrane sphingolipids and ceramides can be
delivered to lysosomes during the delivery of raft com-
ponents. It is generally accepted that sphingolipids are
hydrolyzed in lysosomes to sphingosine and reutilized
for sphingolipid biosynthesis.
Sphingolipid and ceramide metabolism in the plasma
The major sphingolipid present in the human plasma is
sphingomyelin (~90%) and different ceramides consti-
tute the rest of sphingolipids [30]. Sphingomyelin and
ceramides are found associated with plasma lipoproteins.
The concentrations of these lipids appear to follow the
size of the particles; very low density lipoproteins have
the highest while high density lipoproteins have the low-
est concentrations [30]. Since VLDL concentrations are
considerably lower than other lipoproteins, the amounts
of sphingolipids carried by these lipoproteins in the
plasma are lower than those of LDL and HDL.
There is paucity of knowledge about the metabolism
of sphingolipids in the plasma compartment. Due to
their structural similarities and localization on the sur-
face of lipoproteins, sphingolipid catabolism is expected
Figure 1 Pathways involved in cellular homeostasis of ceramides: The diagram shows the synthesis of ceramides in the endoplasmic
reticulum (ER). This involves de novo synthesis (A), hydrolysis of sphingomyelin at the plasma membrane (B), and delivery of sphingolipids to
lysosomes (C) for recycling. From the ER, ceramides are transported to the Golgi by ceramide transport protein (CERT) and converted to different
sphingolipids. These sphingolipids are then transported to the plasma membrane (PM), to plasma, and and to lysosomes. Various mechanisms
involved in the transport of ceramides and sphingolipids in different subcellular compartments are discussed in the review. Cer-1P, ceramide 1
phosphate; CPE, ceramide phosphoethanolamine; SMS, sphingomyelin synthase; Galcer, galactosylceramide; Glucer, glucosylceramide; LacCer,
lactosylceramide; GM3, ganglioside GM3.
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Nascent plasma lipoproteins are hydrolyzed at endothe-
lial cell surfaces by the action of lipoprotein lipases
resulting in the hydrolysis of triglycerides and phospholi-
pids and shedding of some of the surface components
[31,32]. It is unknown whether sphingolipids remain
associated with lipoproteins during and after lipase ac-
tion. However, it is known that PLTP can transfer
sphingomyelin from vesicles to HDL [33]. Hydrolyzed
lipoprotein remnants are removed from the plasma via
endocytosis involving members of the LDL receptor
family [34]. It is likely that some of the sphingolipids are
taken by cells during endocytosis of apoB-containing
lipoproteins. Thus, sphingolipid catabolism might follow
the path of their lipoprotein carriers; however, experi-
mental evidence for this lacking.
Mechanisms controlling ceramide levels in
different subcellular compartments: a hypothesis
To study the importance of sphingomyelin production
on cellular and plasma ceramide homeostasis, we gener-
ated SMS1 and SMS2 deficient mice with the hypothesis
that ablation of these enzymes will lead to excessaccumulation of ceramides, cellular apoptosis and em-
bryonic lethality. However, individual knockout of these
genes was not embryonic lethal. Analysis of various
sphingolipids in macrophages, liver and plasma revealed
unexpected knowledge. Individual ablation of these
enzymes decreased plasma sphingomyelin by about 50%
(Table 1) [25]; therefore, these two enzymes contribute
equally to plasma sphingomyelin levels. Surprisingly,
SMS1 deficiency had no effect, while SMS2 deficiency
increased plasma ceramide levels (Table 1) [25]. More
importantly, SMS1, but not SMS2, knockout mice had
4–7 fold increase in glucosylceramide and GM3 in the
plasma and tissues. To explain these unexpected obser-
vations, we advance the hypothesis that cells have
evolved several mechanisms to control ceramide levels
in different sub-cellular compartments (Figure 2). First,
cells maintain ceramide levels in the ER involving
de novo synthesis (Figure 2.1a) and protein mediated ex-
port (Figure 2.1b). Second, enzymatic conversion of cer-
amides to various sphingolipids is the major mechanism
regulating ceramide levels in the Golgi complex
(Figure 2.2a). Further, they can be secreted with apoB-
containing lipoproteins in some cells (Figure 2.2b).
Table 1 Levels of various sphingolipids in wildtype and SMS knockout mice
SM PC Cer GluCer GM3
Plasma nmol/ml ng/ml
Wildtype 105± 5 1443± 109 805 ± 33 3714 ± 358 342± 22
Sms1 KO 52± 3* 1322± 99 888 ± 80 25705 ± 2317* 1996 ± 219*
Wildtype 95 ± 3 1301± 78 796 ± 55 3209 ± 277 329± 34
Sms2 KO 47± 3* 1232± 102 1032± 50* 3638 ± 421 367± 51
Liver nmol/mg protein ng/mg protein
Wildtype 11 ± 2 102 ± 38 247 ± 29 104 ± 10 22 ± 2
Sms1 KO 7± 1* 108 ± 21 184 ± 21* 396 ± 31* 120± 13*
Wildtype
Sms2 KO 8± 1* 130 ± 15 284 + 42 109 ± 19 19 ± 5
Macrophages
Wildtype 63 ± 7 117 ± 22 985 ± 98 85 ± 17 151± 50
Sms1 KO 19± 5* 131 ± 19 1027± 128 1019 ± 26* 1255± 77*
Wildtype 61 ± 6 157 ± 33 890 ± 109 111 ± 20 103± 12
Sms2 KO 51± 2* 139 ± 23 962 ± 91 130 ± 18 99 ± 7
Different sphingolipids were quantified by LC/MS/MS from tissues obtained from wildtype and SMS1 and SMS2 knockout mice. Statistical significance was
evaluated using Student t-test. Values are mean ± SD, n = 6. *P<0.01. SM, sphingomyelin; PC, phosphatidylcholine; Cer, ceramide; DHCer, dihydroceramide; Glucer,
glucosylceramide; Sph, sphingosine; S1P, sphingosine-1-phosphate; Sa1P, sphinganine-1-phosphate; GM3, ganglioside GM3. Data are modified from [25].
Figure 2 Hypothesized mechanisms controlling ceramide levels
in various subcellular organelles: 1. Control of ceramide levels in
the endoplasmic reticulum involves (a) de novo synthesis (a) and
CERT mediated transfer to Golgi (b). 2. Regulation of ceramide levels
in the Golgi compartment may involve (a) conversion to other
sphingolipids such as sphingomyelin and glucosylceramides, and (b)
incorporation into apoB-containing lipoproteins for secretion. 3.
Maintenance of ceramide levels in the plasma membrane (PM)
consists of (a) conversion to sphingomyelin, (b) delivery to
lysosomes, and (c) efflux to plasma lipoproteins.
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and efflux mechanisms might be involved in the control
of ceramide levels in the plasma membrane (Figure 2.3).
Controlling ceramides in the endoplasmic reticulum
Three different pathways can be envisioned for the
transport of ceramides from the ER to Golgi; vesicular
transport, incorporation into lipoproteins, and protein
mediated transport. Ceramides can be transported to the
Golgi as part of the vesicular trafficking that is well
described for protein secretion. In this pathway, trans-
port vesicles bud off from the ER and then fuse with cis-
Golgi. Lipoproteins are assembled in the ER and trans-
ported to Golgi via special transport vesicles [35,36]. Ob-
viously, ceramides could become part of lipoprotein and
protein transport vesicles and be transported to the
Golgi. However, this vesicular trafficking pathway might
be slow and not sufficing to control ceramide levels that
are actively synthesized in the ER compartment.
A significant understanding about the regulated
process of ceramide movement from the ER to Golgi
came with the identification of ceramide transfer protein
(CERT) that picks up ceramides from the ER membrane
and deposits them into the Golgi membrane independ-
ent of the vesicular trafficking. CERT is essential for em-
bryonic survival perhaps because CERT deficiency-
mediated ceramide accumulation can cause severe devel-
opmental disruption without inducing apoptosis [21-23].
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pathway and indicate that vesicular trafficking either as
part of membranes or lipoproteins is perhaps not a
major pathway for ceramide transport from the ER to
Golgi or plasma.
Regulating ceramides in the Golgi
We envision at least two different mechanisms involved
in the control of ceramides in this compartment. First
involves vesicular trafficking that is well described for
the transport of proteins from the Golgi to the plasma
membrane. This process involves exit of vesicles from
the trans-Golgi and their subsequent fusion with the
plasma membrane. Second, at least in lipoprotein syn-
thesizing tissues such as liver, intestine and heart, sphin-
golipids and ceramides could become part of newly
synthesized triglyceride-rich apolipoprotein B-containing
lipoproteins in the Golgi. There is significant evidence in
the literature for this mechanism. It has been reported
that the major carriers of ceramide in the plasma are
very low density lipoproteins (VLDL) [30]. Studies in
hamsters suggest that de novo ceramides are secreted via
VLDL/LDL pathway by the liver [37,38]. Moreover, iso-
lated rat hepatocytes have been shown to secrete cera-
mides as part of apoB-containing particles [39].
Activation of serine palmitoyl transferase, the rate-
limiting enzyme in the de novo ceramide synthesis by
palmitic acid but not other fatty acids elevates VLDL
and LDL ceramides. Inhibition of de novo ceramide syn-
thesis by Fumonisin B1 prevents the incorporation of
ceramide in apoB-containing particles [39]. Despite the
evidence that hepatocytes secrete ceramides with VLDL,
it remains to be determined how ceramides and possibly
sphingolipids are deposited in nascent lipoproteins.
There are two candidate proteins that could play a role
in this process. First, microsomal triglyceride transfer
protein [40,41], which transfers several lipids, can trans-
fer sphingolipids and deposit them in nascent lipopro-
teins. Second, phospholipid transfer protein [33,42,43]
can transfer these lipids onto nascent lipoproteins. Alter-
natively, there might be other yet unidentified proteins
that could specifically transfer sphingolipids to lipopro-
teins. Thus, ceramide levels can be regulated by vesicular
trafficking of membranes and lipoproteins.
Due to the possible existence of these two pathways,
we had anticipated that SMS1 and SMS2 deficiencies will
decrease sphingomyelin and increase ceramides in cells
and plasma. To test this, we measured different lipids in
the plasma, liver and macrophages of SMS1 and SMS2
deficient mice (Table 1) [25,26]. SMS1 and SMS2 defi-
ciency had no effect on phosphatidylcholine levels. How-
ever, their deficiencies had significant effects on cellular
and plasma sphingomyelin, ceramide, glucosylceramides
and gangliosides such as GM3. The SMS1 deficient micehad normal levels of plasma ceramides. By contrast,
SMS2 knockout mice had significantly increased plasma
ceramides [25,26]. Since, SMS1 is mainly present in the
Golgi, we had anticipated that ceramides would accumu-
late in cells. Instead, we found significant reductions
(−26%, p<0.01) in hepatic ceramides in SMS1 deficient
mice. To our surprise, we found that both glucosylcera-
mide and GM3 were dramatically increased (7-fold and
6-fold, respectively) in SMS1 deficient mouse plasma,
but not in SMS2 ablated animals (Table 1). Further, glu-
cosylceramide and GM3 were also increased by 4- and 6-
fold, respectively, in the livers of SMS1 deficient mice
compared to controls due to increases in ceramide gluco-
syltransferase [25]. Similar changes were also noted in
macrophages. However, SMS2 deficiency had no effect
on glucosylceramide and GM3 levels in the plasma, liver
and macrophages (Table 1) [25]. These data show that
SMS1 deficiency increases cellular and plasma glucosyl-
ceramide and GM3 with no significant effect on plasma
ceramide.
To explain these observations, we propose that Golgi
ceramide levels are controlled by their enzymatic con-
version to different sphingolipids. Cells have evolved dif-
ferent enzymes to convert ceramides into various
sphingolipids (Figure 1). Hence, deficiency in the Golgi
sphingomyelin synthesis, as in the absence of SMS1,
results in the shunting of ceramides to glucosylceramide
and ganglioside synthesis. Based on this hypothesis, we
predict that deficiency in glucosylceramide synthesis will
increase cellular and plasma sphingomyelin levels. A
consequence of enhanced synthesis of different sphingo-
lipids is their accumulation in cells. Obviously, this can
be tolerated to some extent and could explain their
higher cellular levels. However, we anticipate that excess
amounts would be deleterious. Therefore, other mechan-
isms must exist to lower sphingolipids in the Golgi. This
might involve their secretion possibly as part of apoB-
lipoproteins and could explain increases in plasma levels
of glucosylceramide and GM3 in SMS1 deficient mice.
Thus, conversion of ceramides to different sphingolipids
and secretion of these sphingolipids with apoB-
lipoproteins might be the two major pathways that con-
trol Golgi ceramide levels.
Maintaining plasma membrane ceramide levels
As discussed above, ceramides are likely not brought to
the plasma membrane from the ER involving transport
vesicles. Instead, plasma membrane ceramides are prob-
ably generated from sphingomyelin by sphingomyeli-
nases. It has been known for some time that SMS2
primarily resides in the plasma membrane [19]. There-
fore, ablation of SMS2 is expected to increase cellular
ceramides due to their increase in plasma membrane.
Alternatively, cells might have high glucosylceramides
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saw significant increases in cellular ceramides nor in glu-
cosylceramide/GM3. No change in glucosylceramide/
GM3 could be a consequence of the absence of the
enzymes that convert ceramides to these lipids in the
plasma membrane. It is possible that plasma membrane
ceramides can be maintained by their delivery to lyso-
somes as part of the endocytic vesicles that bring extra-
cellular or membrane components to lysosomes for
destruction or reutilization. In this pathway, sphingoli-
pids are hydrolyzed in the lysosomal compartment and
ceramides are salvaged for further utilization. However,
this is also expected to increase cellular ceramide levels
or sphingomyelin levels due to the presence of SMS1 ac-
tivity in the Golgi of SMS2 knockout mice. But, we did
not observe significant increases in cellular sphingomye-
lin or ceramide levels. Therefore, there must be other
mechanisms that control ceramide levels in the plasma
membrane besides their conversion to sphingomyelin
and reutilization via lysosomes. To explain this, we
propose a third mechanism involving their efflux to
plasma lipoproteins. In this process, ceramides can be
directly given off from the plasma membrane to extra-
cellular lipoproteins. ATP cassette transport proteins or
yet unknown proteins might participate in this process.
It has been reported that ABCG1 but not ABCA1 can
directly mediate sphingomyelin efflux from cells to extra-
cellular HDL [44]. However, no evidence exists for the ef-
flux of ceramides and deserves further investigation.
Perspectives
The purpose of this short review is to advance the con-
cept that cells have evolved different mechanisms to con-
trol ceramide levels in various subcellular organelles. In
the ER, ceramide levels are controlled by its export to the
Golgi by CERT. In the Golgi, ceramide levels are con-
trolled by their conversion to sphingomyelin, glucosylcer-
amides and possibly other sphingolipids. In the plasma
membrane, ceramide are controlled by their conversion
to sphingomyelin and efflux to plasma lipoproteins. Most
of the mechanisms proposed in the control of cellular
ceramides and sphingolipids can be easily tested. The
role of conversion of ceramides to different sphingolipids
can be evaluated by ablating critical enzymes involved in
sphingolipid synthesis such as we have done for SMS1
and SMS2. We anticipate that ablation of glucosylcera-
mide synthase might increase sphingomyelin levels.
The role of apoB-lipoproteins in the secretion of cera-
mides and sphingolipids can be examined in mouse mod-
els that are deficient in apoB, MTP, and/or PLTP.
Mechanisms involving cellular efflux of ceramides and
sphingolipids can be addressed using mouse models of
ABCA1, ABCG1 deficiency. We hope that this review will
generate enthusiasm to focus on various sub-cellularmechanisms involved in the regulation of ceramides and
other sphingolipids.
Abbreviations
ER: Endoplasmic reticulum; SMS: Sphingomyelin synthase; LDL: Low density
lipoproteins; CERT: Ceramide transfer protein.
Competing interests
The author(s) declare that they have no competing interests'.
Authors’ contributions
MMH wrote, edited, and submitted the manuscript; WJ and XJ provided
critical comments; the table is from XJ; MMH made the figures. All authors
read and approved the final manuscript.
Acknowledgements
This work was supported in part by NIH grants DK-46900 and HL-95924 to
MMH and HL093419 and HL69817 to XCJ.
Received: 20 June 2012 Accepted: 13 July 2012
Published: 31 July 2012
References
1. Gault CR, Obeid LM, Hannun YA: An overview of sphingolipid metabolism:
from synthesis to breakdown. Adv Exp Med Biol 2010, 688:1–23.
2. Sabourdy F, Kedjouar B, Sorli SC, Colie S, Milhas D, Salma Y, et al: Functions
of sphingolipid metabolism in mammals–lessons from genetic defects.
Biochim Biophys Acta 2008, 1781:145–183.
3. Lucki NC, Sewer MB: Nuclear sphingolipid metabolism. Annu Rev Physiol
2012, 74:131–151.
4. Hannun YA, Obeid LM: Many ceramides. J Biol Chem 2011, 286:
27855–27862.
5. Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997,
387:569–572.
6. Futerman AH, Hannun YA: The complex life of simple sphingolipids.
EMBO Rep 2004, 5:777–782.
7. Holthuis JC, van Meer G, Huitema K: Lipid microdomains, lipid
translocation and the organization of intracellular membrane transport
(Review). Mol Membr Biol 2003, 20:231–241.
8. Gulbins E, Li PL: Physiological and pathophysiological aspects of
ceramide. Am J Physiol Regul Integr Comp Physiol 2006, 290:R11–R26.
9. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-
Munding CC, et al: Ceramide accumulation mediates inflammation, cell
death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:
382–391.
10. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, et al:
Liver cell death and anemia in Wilson disease involve acid
sphingomyelinase and ceramide. Nat Med 2007, 13:164–170.
11. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, et al:
Plasma ceramides are elevated in obese subjects with type 2 diabetes
and correlate with the severity of insulin resistance. Diabetes 2009,
58:337–343.
12. Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, et al:
Plasma ceramide and lysophosphatidylcholine inversely correlate with
mortality in sepsis patients. J Lipid Res 2003, 44:754–761.
13. Chatterjee S: Sphingolipids in atherosclerosis and vascular biology.
Arterioscler Thromb Vasc Biol 1998, 18:1523–1533.
14. Gulbins E, Kolesnick R: Raft ceramide in molecular medicine. Oncogene 2003,
22:7070–7077.
15. de Mello V, Lankinen M, Schwab U, Kolehmainen M, Lehto S, Seppanen-
Laakso T, et al: Link between plasma ceramides, inflammation and insulin
resistance: association with serum IL-6 concentration in patients with
coronary heart disease. Diabetologia 2009, 52:2612–2615.
16. Ichi I, Takashima Y, Adachi N, Nakahara K, Kamikawa C, Harada-Shiba M, et
al: Effects of dietary cholesterol on tissue ceramides and oxidation
products of apolipoprotein B-100 in ApoE-deficient mice. Lipids 2007,
42:893–900.
17. Bikman BT, Summers SA: Ceramides as modulators of cellular and whole-
body metabolism. J Clin Invest 2011, 121:4222–4230.
18. Hannun YA: Functions of ceramide in coordinating cellular responses to
stress. Science 1996, 274:1855–1859.
Hussain et al. Nutrition & Metabolism 2012, 9:71 Page 7 of 7
http://www.nutritionandmetabolism.com/content/9/1/7119. Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC: Identification
of a family of animal sphingomyelin synthases. EMBO J 2004, 23:33–44.
20. Vacaru AM, Tafesse FG, Ternes P, Kondylis V, Hermansson M, Brouwers JF, et
al: Sphingomyelin synthase-related protein SMSr controls ceramide
homeostasis in the ER. J Cell Biol 2009, 185:1013–1027.
21. Hanada K: Intracellular trafficking of ceramide by ceramide transfer
protein. Proc Jpn Acad Ser B Phys Biol Sci 2010, 86:426–437.
22. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, et al:
Molecular machinery for non-vesicular trafficking of ceramide.
Nature 2003, 426:803–809.
23. Hanada K, Kumagai K, Tomishige N, Yamaji T: CERT-mediated trafficking of
ceramide. Biochim Biophys Acta 2009, 1791:684–691.
24. Yamaoka S, Miyaji M, Kitano T, Umehara H, Okazaki T: Expression cloning of
a human cDNA restoring sphingomyelin synthesis and cell growth in
sphingomyelin synthase-defective lymphoid cells. J Biol Chem 2004,
279:18688–18693.
25. Li Z, Fan Y, Liu J, Li Y, Quan C, Bui HH, et al: Impact of Sphingomyelin
Synthase 1 Deficiency on Sphingolipid Metabolism and Atherosclerosis
in Mice. Arterioscler Thromb Vasc Biol 2012, 32:1577–1584.
26. Liu J, Zhang H, Li Z, Hailemariam TK, Chakraborty M, Qiu D, et al:
Sphingomyelin Synthase 2 Is One of the Determinants for Plasma and
Liver Sphingomyelin Levels in Mice. Arterioscler Thromb Vasc Biol 2009,
29:850–856.
27. Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, Sato SB, et al: Role of
membrane sphingomyelin and ceramide in platform formation for Fas-
mediated apoptosis. J Exp Med 2005, 202:249–259.
28. van der Luit AH, Budde M, Zerp S, Caan W, Klarenbeek JB, Verheij M, et al:
Resistance to alkyl-lysophospholipid-induced apoptosis due to
downregulated sphingomyelin synthase 1 expression with consequent
sphingomyelin- and cholesterol-deficiency in lipid rafts.
Biochem J 2007, 401:541–549.
29. Li Z, Hailemariam TK, Zhou H, Li Y, Duckworth DC, Peake DA, et al:
Inhibition of sphingomyelin synthase (SMS) affects intracellular
sphingomyelin accumulation and plasma membrane lipid organization.
Biochim Biophys Acta 2007, 1771:1186–1194.
30. Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B,
et al: Blood sphingolipidomics in healthy humans: impact of sample
collection methodology. J Lipid Res 2010, 51:3074–3087.
31. Hussain MM, Pan X: Clock genes, intestinal transport and plasma lipid
homeostasis. Trends Endocrinol Metab 2009, 20:177–185.
32. Hussain MM, Kancha RK, Zhou Z, Luchoomun J, Zu H, Bakillah A:
Chylomicron assembly and catabolism: role of apolipoproteins and
receptors. Biochim Biophys Acta 1996, 1300:151–170.
33. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al: Targeted mutation
of plasma phospholipid transfer protein gene markedly reduces high-
density lipoprotein levels. J Clin Invest 1999, 103:907–914.
34. Hussain MM, Strickland DK, Bakillah A: The mammalian low-density
lipoprotein receptor family. Annu Rev Nutr 1999, 19:141–172.
35. Mansbach CM, Siddiqi SA: The biogenesis of chylomicrons. Annu Rev
Physiol 2010, 72:315–333.
36. Tiwari S, Siddiqi SA: Intracellular Trafficking and Secretion of VLDL.
Arterioscler Thromb Vasc Biol 2012, 32:1079–1086.
37. Memon RA, Holleran WM, Moser AH, Seki T, Uchida Y, Fuller J, et al:
Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and
produce lipoproteins enriched in ceramides and sphingomyelin.
Arterioscler Thromb Vasc Biol 1998, 18:1257–1265.
38. Memon RA, Holleran WM, Uchida Y, Moser AH, Ichikawa S, Hirabayashi Y, et
al: Regulation of glycosphingolipid metabolism in liver during the acute
phase response. J Biol Chem 1999, 274:19707–19713.
39. Merrill AH Jr, Lingrell S, Wang E, Nikolova-Karakashian M, Vales TR, Vance DE:
Sphingolipid biosynthesis de novo by rat hepatocytes in culture.
Ceramide and sphingomyelin are associated with, but not required for,
very low density lipoprotein secretion. J Biol Chem 1995, 270:13834–
13841.
40. Hussain MM, Shi J, Dreizen P: Microsomal triglyceride transfer protein and
its role in apolipoprotein B-lipoprotein assembly. J Lipid Res 2003,
44:22–32.
41. Hussain MM, Rava P, Walsh M, Rana M, Iqbal J: Multiple functions of
microsomal triglyceride transfer protein. Nutr Metab (Lond) 2012, 9:14.42. Jiang XC, Qin S, Qiao C, Kawano K, Lin M, Skold A, et al: Apolipoprotein B
secretion and atherosclerosis are decreased in mice with phospholipid-
transfer protein deficiency. Nat Med 2001, 7:847–852.
43. Jiang XC, Jin W, Hussain MM: Phospholipid transfer activity and apoB-
containing lipoprotein metabolism. Nutr Metab (Lond) 2012, :. In press.
44. Kobayashi A, Takanezawa Y, Hirata T, Shimizu Y, Misasa K, Kioka N, et al:
Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1.
J Lipid Res 2006, 47:1791–1802.
doi:10.1186/1743-7075-9-71
Cite this article as: Hussain et al.: Mechanisms involved in cellular
ceramide homeostasis. Nutrition & Metabolism 2012 9:71.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
